Vivimed Labs Ltd.

BSE: VIVIMEDLAB532660ISIN INE526G01021

Healthcare
Pharmaceuticals

Share price

₹5.88-0.11 (-1.84%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹27.99
52W low: ₹4.76
Off 52W high: -78.99%
1M return: -0.17%
3M return: +14.84%
6M return: -12.24%
1Y return: —
20D avg volume: 12,122
50 DMA: ₹6.12
200 DMA: ₹6.80

Key ratios Consolidated

Market cap: ₹48.75 Cr
Current price: ₹5.88
52W high / low: ₹27.99 / ₹4.76
Face value: ₹2.00
P/E: -0.28
P/B: —
EPS (TTM): ₹-21.15
Book value / share: —
ROE: —
ROCE: -56.00%
Operating margin: —
Net margin: —
Debt / equity: -1.89
Net debt: ₹397.24 Cr
Interest cover: -41.03
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 25.1 days

Financials

Metric	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24
Income statement
	12.00	15.99	20.61	21.39	25.61	36.51	24.77	29.37	38.62	41.46	33.64	35.35
	5.75	0.00	0.21	0.38	4.22	0.07	0.03	0.06	7.62	0.04	2.20	0.11
	17.75	15.99	20.82	21.77	29.83	36.58	24.80	29.43	46.24	41.50	35.84	35.46
	163.65	32.54	28.13	27.26	34.84	42.55	29.94	44.68	39.59	58.10	56.14	51.04
	7.91	8.93	5.30	10.77	7.76	14.71	15.47	19.82	33.89	20.83	17.36	17.46
	0.00	0.00	0.00	0.00	0.00	—	—	—	1.41	0.63	—	0.78
	9.97	3.69	5.60	5.71	8.79	7.29	6.29	6.03	6.99	9.75	9.78	7.63
	0.95	1.00	1.66	0.58	1.74	0.48	0.43	0.30	33.33	13.21	11.89	10.66
	11.51	4.63	4.90	5.01	5.49	6.62	4.10	4.01	5.83	4.70	4.70	4.70
	94.29	15.32	6.85	6.17	7.38	8.47	7.76	16.99	40.38	8.67	12.02	9.97
	-145.90	-16.55	-7.30	-5.49	-5.01	-5.97	-5.14	-15.24	6.65	-16.60	-20.30	-15.57
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	-145.90	-16.55	-7.30	-5.49	-5.01	-5.97	-5.14	-15.24	6.65	-16.60	-20.30	-15.57
	0.14	0.00	0.00	0.00	0.11	0.00	0.00	0.00	1.39	0.55	0.00	0.00
	-146.03	-16.55	-7.30	-5.49	-5.13	-5.97	-5.14	-15.24	5.26	-16.05	-20.30	-15.57
	-17.74	-0.88	-0.88	-0.66	-0.67	-0.72	-0.60	-1.84	0.64	-1.94	-2.45	1.88
Key metrics
	-133.44	-10.92	-0.74	0.10	2.22	1.13	-0.61	-10.93	45.81	1.31	-3.71	-0.21
	-1,112.00%	-68.30%	-3.60%	0.50%	8.70%	3.10%	-2.50%	-37.20%	118.60%	3.20%	-11.00%	-0.60%
	-1,216.90%	-103.50%	-35.40%	-25.70%	-20.00%	-16.40%	-20.80%	-51.90%	13.60%	-38.70%	-60.30%	-44.00%
	-47.50%	—	-1.20%	—	-0.60%	—	—	—	—	—	—	—
	-53.10%	-56.20%	-16.80%	-27.20%	-33.70%	-11.90%	-26.40%	-16.90%	—	—	—	—
	-2,746.60%	-177.20%	-42.00%	64.00%	-197.50%	62.80%	74.70%	2.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	69.99	69.99	116.27	149.07
	6.34	6.32	4.37	9.98
	76.33	76.31	120.64	159.05
	251.58	251.56	152.03	204.87
	32.91	32.91	57.76	89.55
	0.00	0.00	0.00	—
	24.97	24.97	28.39	34.16
	4.19	4.17	2.95	2.43
	26.05	26.05	20.22	19.94
	122.63	122.62	40.61	71.04
	-175.24	-175.25	-31.39	-45.82
	0.00	0.00	0.00	0.00
	-175.24	-175.25	-31.39	-45.82
	0.14	0.14	0.11	0.38
	-175.37	-175.38	-31.50	-45.45
	-20.16	-21.15	-3.85	-5.48
Key metrics
	-145.00	-145.03	-8.22	-23.45
	-207.17%	-207.20%	-7.10%	-15.70%
	-250.56%	-250.60%	-27.10%	-30.50%
	—	-56.00%	-5.50%	—
	-39.80%	-39.80%	-22.00%	—
	—	-456.80%	30.70%	—
	—	7.70	-15.34	—
	—	-0.04	0.34	—
	—	-1.89	—	—
	—	397.24	—	—
	—	25.1	293.4	—
Balance sheet
	—	753.48	920.83	—
	—	168.00	327.56	—
	—	0.07	0.71	—
	—	45.33	74.11	—
	—	12.71	58.76	—
	—	63.48	98.53	—
	—	237.01	254.40	—
	—	53.24	39.42	—
	—	448.11	408.20	—
	—	397.31	—	—
	—	325.80	—	—
	—	71.51	—	—
	—	-210.55	—	—
Cash flow
	—	7.70	-10.81	—
	—	-0.95	4.53	—
	—	-6.11	4.96	—
	—	0.00	-4.53	—

Metric	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24
Income statement
	7.55	11.63	18.66	17.94	22.57	34.23	22.16	24.64	36.39	37.13	30.28	33.00
	0.00	0.00	0.16	0.36	4.15	0.00	0.03	0.00	7.37	0.04	2.16	0.01
	7.55	11.63	18.82	18.30	26.73	34.24	22.19	24.64	43.76	37.17	32.44	33.01
	148.73	28.20	26.26	23.80	30.56	41.21	27.18	39.75	36.47	53.89	51.99	48.39
	9.30	6.96	6.01	10.11	12.34	15.81	15.02	16.95	30.92	19.76	16.99	17.72
	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—	—
	8.64	2.68	4.58	4.51	7.07	5.93	5.09	4.95	5.69	8.59	8.59	6.57
	0.79	0.94	1.60	0.52	1.48	0.43	0.37	0.25	33.69	13.16	11.82	10.61
	4.30	4.40	4.68	4.80	4.61	6.37	3.86	3.79	4.96	4.49	4.49	4.49
	89.13	14.24	5.57	4.83	5.89	7.07	6.94	16.27	41.37	7.59	—	9.15
	-141.18	-16.57	-7.45	-5.50	-3.84	-6.97	-4.99	-8.05	7.28	-16.72	-19.56	-15.38
	0.00	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	-141.18	-16.57	-7.45	-5.50	-3.84	-6.97	-4.99	-15.11	7.28	-16.72	-19.56	-15.38
	0.00	0.00	0.00	0.00	0.00	—	—	—	1.77	0.55	—	—
	-141.18	-16.57	-7.45	-5.50	-3.84	-6.97	-4.99	-15.11	5.51	-16.17	-19.56	-15.38
	-17.14	-2.00	-0.90	-0.66	-0.60	-0.84	-0.60	-1.82	0.67	-1.95	-2.36	1.86
Key metrics
	-136.09	-11.23	-1.17	-0.18	2.25	-0.17	-0.76	-11.07	45.93	0.93	-3.25	-0.28
	-1,802.50%	-96.60%	-6.30%	-1.00%	10.00%	-0.50%	-3.40%	-44.90%	126.20%	2.50%	-10.70%	-0.80%
	-1,869.90%	-142.50%	-39.90%	-30.70%	-17.00%	-20.40%	-22.50%	-61.30%	15.10%	-43.50%	-64.60%	-46.60%
	-174.70%	—	-2.50%	—	-1.00%	—	—	—	—	—	—	—
	-66.50%	-66.00%	-15.80%	-27.20%	-38.00%	-7.80%	-26.80%	-25.30%	—	—	—	—
	-3,576.60%	-137.70%	-49.30%	63.60%	-169.70%	56.90%	74.50%	1.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	55.78	55.78	103.60	136.80
	0.52	0.51	4.18	9.57
	56.30	56.30	107.79	146.37
	226.99	226.98	138.71	190.75
	32.38	32.39	60.12	85.39
	0.00	0.00	0.00	—
	20.41	20.41	23.04	29.45
	3.85	3.86	2.53	1.90
	18.18	18.19	18.63	18.41
	113.77	113.76	36.16	67.84
	-170.70	-170.68	-30.92	-44.38
	0.00	0.00	—	—
	-170.70	-170.68	-30.92	-44.38
	0.00	0.00	0.00	—
	-170.70	-170.68	-30.92	-44.38
	-20.70	-20.59	3.87	-5.35
Key metrics
	-148.67	-148.63	-9.76	-24.07
	-266.53%	-266.50%	-9.40%	-17.60%
	-306.02%	-306.00%	-29.80%	-32.40%
	—	-207.60%	-11.60%	—
	-46.16%	-46.20%	-24.30%	—
	—	-452.00%	30.30%	—
	—	4.45	5.74	—
	—	-0.03	-0.19	—
	—	-3.46	—	—
	—	388.04	—	—
	—	16.7	241.9	—
Balance sheet
	—	502.16	638.95	—
	—	142.45	247.78	—
	—	0.07	0.29	—
	—	43.37	45.80	—
	—	10.83	56.50	—
	—	63.12	83.04	—
	—	231.42	247.87	—
	—	51.65	33.65	—
	—	421.81	393.21	—
	—	388.11	—	—
	—	316.75	—	—
	—	71.36	—	—
	—	-112.19	—	—
Cash flow
	—	4.45	5.74	—
	—	-0.11	-4.06	—
	—	-4.55	-2.53	—
	—	0.00	0.00	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -46.16%
Profit YoY (TTM): -452.25%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -39.80%
Profit YoY (TTM): -457.08%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Vivimed Labs Ltd.	49	5.88	-0.28	-56.00%	-39.80% TTM	-457.08% TTM	—

Filings & corporate actions

Recent announcements

intimation of meeting of committee of creditors26 Sep 2026 · Company Update / Intimation of meeting of Committee of Creditors
Seeking time for holding an AGM26 Sep 2026 · Company Update / General
closure of trading window23 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Committee of Creditors meeting on 10th September 20268 Sep 2026 · Company Update / Intimation of meeting of Committee of Creditors
6th COC meeting on 18th August 202617 Aug 2026 · Company Update / Intimation of meeting of Committee of Creditors
re-lodgement of transfer requests22 Jul 2026 · Company Update / General
news paper publication for march 2026 results22 Jul 2026 · Company Update / Newspaper Publication
results for FY 2025-202617 Jul 2026 · Result / Financial Results
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/07/2026 ,inter alia, to consider and approve quarter & year end results (31.3.2026)14 Jul 2026 · Board Meeting / Board Meeting
Certificate under reg 74(5)10 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
window closure30 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
form G17 Jun 2026 · Company Update / Updates - Corporate Insolvency Resolution Process (CIRP)
Board meeting Postponed30 May 2026 · Company Update / General
The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 28/05/2026 has been revised to 30/05/202626 May 2026 · Company Update / Board Meeting Rescheduled
annual secretarial compliance report19 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve audited results for FY 2025-202617 May 2026 · Board Meeting / Board Meeting
Form A - Public Announcement23 Apr 2026 · Company Update / Public Announcement
ADMISSION TO CIRP17 Apr 2026 · Company Update / General
certificate under reg 74(5)8 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Initial disclosure- Not Large corporate6 Apr 2026 · Company Update / General
CLOSURE OF TRADING WINDOW2 Apr 2026 · Insider Trading / SAST / Closure of Trading Window
Q3 FY 2026 RESULTS13 Mar 2026 · Result / Financial Results
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2026 ,inter alia, to consider and approve Notice of Board meeting9 Mar 2026 · Board Meeting / Board Meeting
updates (additional information)16 Feb 2026 · Company Update / General
Application filed for initiation of PPIRP13 Feb 2026 · Company Update / General
The Board Meeting to be held on 13/02/2026 Stands Cancelled.11 Feb 2026 · Board Meeting / Board Meeting
updates9 Feb 2026 · Company Update / General
Resignation of CFO6 Feb 2026 · Company Update / Resignation of Chief Financial Officer (CFO)
disclosure under regulation 303 Feb 2026 · Company Update / General
Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 31st december 2025 results2 Feb 2026 · Board Meeting / Board Meeting
Re-lodgment of transfer requests for physical shares13 Jan 2026 · Company Update / General
regulation 74(5)7 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
clarification on price movement6 Jan 2026 · Company Update / General
The Exchange has sought clarification from Vivimed Labs Ltd on January 5, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....5 Jan 2026 · Company Update / Clarification
Closure of Trading Window24 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Trading in equity shares will resume from December 18,202511 Dec 2025 · Company Update / General
Voting Results and Scrutinizer''s Report10 Dec 2025 · AGM/EGM / EGM
Proceedings of EGM held on 10.12.202510 Dec 2025 · AGM/EGM / EGM
Post dispatch of Notice of EGM Newspaper add21 Nov 2025 · Company Update / General
Pre dispatch of Notice of EGM Newspaper add21 Nov 2025 · Company Update / General

Board meetings

17 Jul 2026 Board Meeting - Financial Results